alexa Design And Development Of Cancer Drugs By Addressing Genomics Abnormalities
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

2nd International Summit on Clinical Pharmacy
December 02-03, 2014 DoubleTree by Hilton Hotel San Francisco Airport, USA

Rathindra N. Bose, Shadi Moghaddas, HomaDezverah, and Lu Yang
Accepted Abstracts: Clinic Pharmacol Biopharm
DOI: 10.4172/2167-065X.S1.008
It is universally accepted that cancer is a genetic disease. Advances in human genomicshaveoffered us comprehensive knowledge to decipher mutations of specific genes responsible for cancer initiation and progression. An understanding of genetic aberrations, especially those of cancer causing genes, has offered hopes to treat specific cancers by a variety of strategies. Although gene therapy to infuse correct genes which are devoid of mutations and immunotherapy to boost immune systems remain attractive strategies, an explosive growth in the development of targeted cancer therapy to effectively treat specific types of cancerhas emerged. These therapies have targeted specific genes responsible for promoting tumor growth, angiogenesis, and metastasis. The first part of the presentation will focus on the effectiveness of a select group of anticancer compounds to treat breast, ovarian, colon and lung cancers. The second part of the talk will focus on the resistance to treatment, and reoccurrence of the disease after brief remission. The final portion of the talk will concentrate on the development of multitarget therapy from my laboratory. This multi-target therapy is based on the development of a new class of small molecules, phosphaplatins, that effectively promote a variety of tumor suppression and apoptotic genes that include FAS, PTEN, P53, PUMA, and Bax, and concomitantly inhibit angiogenesis by activating PEDF and suppressing VEGFR2 genes. The signaling mechanisms of phosphaplatins to trigger apoptosis, anti-angiogenesis, and anti-metastasis will be presented. The effectiveness of phosphaplatins will also be compared with those of combinational therapies in preclinical settings.
Rathindra N. Bose, Ph.D., is the Vice Chancellor and Vice President for Research and Technology Transfer at the University of Houston System and University of Houston. He is a tenured professor in the department of Chemistry, and holds joint appointments in the departments Biology and Biochemistry and Pharmacological & Pharmaceutical Sciences. He received his Ph.D. degree in Chemistry from Georgetown University, Washington D.C. Among Dr. Bose?s achievements include the discovery of a new class of multi-target anticancer agents, that exhibits excellent efficacy against metastatic ovarian, lung, and head and neck cancers without exhibiting severe toxicity.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version